心血管

订阅

MedSci主页 / 所有栏目 / 心血管

MedSci 专访天士力苏晶： 芪参益气滴丸治疗中国心衰患者多中心研究启动

2015-10-22 MedSci MedSci原创

心衰芪参益气滴丸中国研究
关注

MedSci：苏总，您好！感谢您接受我们的采访。据了解，由天士力研发生产的芪参益气滴丸适应证包括冠心病、心绞痛等病症。目前天士力正在着手开展芪参益气滴丸治疗中国心衰患者的多中心临床研究，请您简要介绍一下芪参益气滴丸对中国心衰患者存在潜在获益的临床证据或理论根据。 苏晶：由天士力研究院和天津中医药大学张伯礼院士团队联合研发的芪参益气滴丸，与天士力复方丹参滴丸在成份上是不同的。芪参益气滴丸的成份主要

MedSci：苏总，您好！感谢您接受我们的采访。据了解，由天士力研发生产的芪参益气滴丸适应证包括冠心病、心绞痛等病症。目前天士力正在着手开展芪参益气滴丸治疗中国心衰患者的多中心临床研究，请您简要介绍一下芪参益气滴丸对中国心衰患者存在潜在获益的临床证据或理论根据。

苏晶：由天士力研究院和天津中医药大学张伯礼院士团队联合研发的芪参益气滴丸，与天士力复方丹参滴丸在成份上是不同的。芪参益气滴丸的成份主要为：黄芪、丹参、三七、降香油。从中医药角度来讲，黄芪的主要作用是提高患者免疫力、增强心肌能量代谢和改善心肌供血。芪参益气滴丸适应证包括冠心病，但在实际临床应用中我们发现，很多在中医上表现为气虚气短的患者，在服用芪参益气滴丸后，上述症状改善比较明显，包括部分检测指标也有很大改善。

众所周知，心力衰竭是心血管疾病的终末期表现。天士力与张健教授及其他在心衰领域比较知名的专家交流过，目前在心功能不全领域的治疗药物还比较有限，特别是西药，近几年在治疗心功能不全方面也鲜有突破性进展。但随着人口老龄化不断加剧和冠心病前期治疗手段的不断改进，患者的存活时间会越来越长，而最终可能会引发或出现心功能不全，所以心功能不全患者数量也会不断增加。因此，基于这样一个背景，天士力开始从中医、中药的角度不断积极探索，希望能从中药的角度为心功能不全患者提供一种更好的治疗手段或者治疗选择，特别是在与西药联合方案方面。因为这类患者病程往往都比较长，病情比较复杂，可能很多脏器都会受到不同程度的牵连和损伤。所以从中医中药的角度来讲，天士力也非常希望与心血管领域的专家们积极开展这方面的探索，这也是天士力开展此项研究的目的。

MedSci：请您简单介绍一下“芪参益气滴丸治疗中国心力衰竭患者多中心随机、双盲、安慰剂对照临床研究”的开展情况？

苏晶：目前这项研究刚刚启动，研究方案已经与张健教授进行了多次完善，基本确定并且得到了包括高润霖院士、黄俊教授等国内心衰领域知名专家的认可。作为天士力目前为止开展的最大规模样本量研究，待该研究方案最终确定后，天士力将与国内多家地区的医院临床研究基地及中心进行沟通。今天通过研究启动发布会的形式，天士力邀请众多研究参与专家进行讨论，以期更好地推动这项研究的顺利进行。

MedSci：众所周知，中药作为中国独有的传统文化，与西药相比在药理方面存在很大差异。请您简单谈谈芪参益气滴丸与治疗心衰的西药相比在药理方面的差异。

苏晶：西药往往为单一靶点治疗，药物成份明确清晰的作用在某一个靶点上，例如ACEI仅仅是作用于抑制血管紧张素转化酶单一靶点上。而对于中药来说，因为属于组份中药。以芪参益气滴丸为例，该药由四味药组成，所以说它是一个多靶点的治疗效果，目前主要体现在改善冠状动脉的供血，提高心肌细胞的耐氧，改善心肌细胞的能量代谢等方面。因此，芪参益气滴丸起到的是一个多靶点的保护作用，能进一步改善患者整体心脏功能，而不是仅就解决一个单一靶点的问题，这也是天士力对中药比较看好的一个原因。

MedSci：请您结合目前中西药在治疗心衰方面的总体情况，展望一下芪参益气滴丸在治疗心衰方面的未来市场前景？

苏晶：天士力对芪参益气滴丸心衰治疗前景非常有信心。如前所述，一方面心衰患者数量会日益增多，另一方面，目前心衰有效治疗方法不多，至少从目前来讲突破性的西药还没有出现。而对于中药，国内有一些药物可能已经尝试开始在做这方面的研究了。而对于天士力来说，作为我国中药现代化的领先企业，紧紧围绕“以中药现代化为核心，集药材种植、药物研发、中间提取、药品制造、市场营销及售后服务于一体”的现代中药产业链建设，获得了包括“最具持续创新力的公司”称号在内的多项国家级荣誉，我们希望从中医中药的角度研发出创新药物，也希望芪参益气滴丸在治疗心衰方面能有突破性的创新和发展。既往，天士力和中国中医科学院张伯礼院士团队已经开展了一项多中心随机化系统在“芪参益气滴丸对心肌梗死二级预防的临床试验研究”项目中的应用“研究，当时获得了国家科技进步二等奖。本次启动这项多中心研究，旨在通过循证医学大样本的研究来证明芪参益气滴丸在治疗心衰方面能够给患者带来更多的获益，改善患者的生存质量和生存时间。对于这项研究天士力是有信心的，同时对于芪参益气滴丸的市场前景也是非常看好的。

注：苏晶，天士力医药营销集团市场部总经理。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (13)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2009639, encodeId=b2fa200963932, content=<a href='/topic/show?id=1b3f4410e62' target=_blank style='color:#2F92EE;'>#天士力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44107, encryptionId=1b3f4410e62, topicName=天士力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Nov 17 16:41:00 CST 2015, time=2015-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909484, encodeId=a4b2190948417, content=<a href='/topic/show?id=16c6430324c' target=_blank style='color:#2F92EE;'>#多中心研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43032, encryptionId=16c6430324c, topicName=多中心研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Tue Jul 12 05:41:00 CST 2016, time=2016-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703194, encodeId=869a1e031943c, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Fri Dec 25 14:41:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903901, encodeId=470e1903901c0, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sun Apr 03 05:41:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41372, encodeId=a253413e261, content=好药, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3911653185, createdName=1ddd0b24m59(暂无匿称), createdTime=Mon Oct 26 18:12:00 CST 2015, time=2015-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41129, encodeId=386a4112937, content=饭, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150904/IMG55E8DB68F05883098.jpg, createdBy=e00a1631985, createdName=fengzhigu, createdTime=Sun Oct 25 17:18:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41054, encodeId=7388410546f, content=中药需要国家投入去研究，肯定有大收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2be01625436, createdName=fatalmelanie, createdTime=Sun Oct 25 13:01:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41055, encodeId=dd3d41055c6, content=加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2be01625436, createdName=fatalmelanie, createdTime=Sun Oct 25 13:01:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40744, encodeId=6f4840e44de, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sat Oct 24 22:16:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373293, encodeId=036713e329341, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sat Oct 24 05:41:00 CST 2015, time=2015-10-24, status=1, ipAttribution=)]
    2015-11-17 meichuangyi

    #天士力#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2009639, encodeId=b2fa200963932, content=<a href='/topic/show?id=1b3f4410e62' target=_blank style='color:#2F92EE;'>#天士力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44107, encryptionId=1b3f4410e62, topicName=天士力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Nov 17 16:41:00 CST 2015, time=2015-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909484, encodeId=a4b2190948417, content=<a href='/topic/show?id=16c6430324c' target=_blank style='color:#2F92EE;'>#多中心研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43032, encryptionId=16c6430324c, topicName=多中心研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Tue Jul 12 05:41:00 CST 2016, time=2016-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703194, encodeId=869a1e031943c, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Fri Dec 25 14:41:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903901, encodeId=470e1903901c0, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sun Apr 03 05:41:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41372, encodeId=a253413e261, content=好药, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3911653185, createdName=1ddd0b24m59(暂无匿称), createdTime=Mon Oct 26 18:12:00 CST 2015, time=2015-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41129, encodeId=386a4112937, content=饭, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150904/IMG55E8DB68F05883098.jpg, createdBy=e00a1631985, createdName=fengzhigu, createdTime=Sun Oct 25 17:18:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41054, encodeId=7388410546f, content=中药需要国家投入去研究，肯定有大收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2be01625436, createdName=fatalmelanie, createdTime=Sun Oct 25 13:01:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41055, encodeId=dd3d41055c6, content=加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2be01625436, createdName=fatalmelanie, createdTime=Sun Oct 25 13:01:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40744, encodeId=6f4840e44de, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sat Oct 24 22:16:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373293, encodeId=036713e329341, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sat Oct 24 05:41:00 CST 2015, time=2015-10-24, status=1, ipAttribution=)]
    2016-07-12 redcrab

    #多中心研究#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2009639, encodeId=b2fa200963932, content=<a href='/topic/show?id=1b3f4410e62' target=_blank style='color:#2F92EE;'>#天士力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44107, encryptionId=1b3f4410e62, topicName=天士力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Nov 17 16:41:00 CST 2015, time=2015-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909484, encodeId=a4b2190948417, content=<a href='/topic/show?id=16c6430324c' target=_blank style='color:#2F92EE;'>#多中心研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43032, encryptionId=16c6430324c, topicName=多中心研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Tue Jul 12 05:41:00 CST 2016, time=2016-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703194, encodeId=869a1e031943c, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Fri Dec 25 14:41:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903901, encodeId=470e1903901c0, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sun Apr 03 05:41:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41372, encodeId=a253413e261, content=好药, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3911653185, createdName=1ddd0b24m59(暂无匿称), createdTime=Mon Oct 26 18:12:00 CST 2015, time=2015-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41129, encodeId=386a4112937, content=饭, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150904/IMG55E8DB68F05883098.jpg, createdBy=e00a1631985, createdName=fengzhigu, createdTime=Sun Oct 25 17:18:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41054, encodeId=7388410546f, content=中药需要国家投入去研究，肯定有大收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2be01625436, createdName=fatalmelanie, createdTime=Sun Oct 25 13:01:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41055, encodeId=dd3d41055c6, content=加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2be01625436, createdName=fatalmelanie, createdTime=Sun Oct 25 13:01:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40744, encodeId=6f4840e44de, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sat Oct 24 22:16:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373293, encodeId=036713e329341, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sat Oct 24 05:41:00 CST 2015, time=2015-10-24, status=1, ipAttribution=)]
    2015-12-25 flyingeagle87

    #专访#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2009639, encodeId=b2fa200963932, content=<a href='/topic/show?id=1b3f4410e62' target=_blank style='color:#2F92EE;'>#天士力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44107, encryptionId=1b3f4410e62, topicName=天士力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Nov 17 16:41:00 CST 2015, time=2015-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909484, encodeId=a4b2190948417, content=<a href='/topic/show?id=16c6430324c' target=_blank style='color:#2F92EE;'>#多中心研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43032, encryptionId=16c6430324c, topicName=多中心研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Tue Jul 12 05:41:00 CST 2016, time=2016-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703194, encodeId=869a1e031943c, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Fri Dec 25 14:41:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903901, encodeId=470e1903901c0, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sun Apr 03 05:41:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41372, encodeId=a253413e261, content=好药, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3911653185, createdName=1ddd0b24m59(暂无匿称), createdTime=Mon Oct 26 18:12:00 CST 2015, time=2015-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41129, encodeId=386a4112937, content=饭, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150904/IMG55E8DB68F05883098.jpg, createdBy=e00a1631985, createdName=fengzhigu, createdTime=Sun Oct 25 17:18:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41054, encodeId=7388410546f, content=中药需要国家投入去研究，肯定有大收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2be01625436, createdName=fatalmelanie, createdTime=Sun Oct 25 13:01:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41055, encodeId=dd3d41055c6, content=加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2be01625436, createdName=fatalmelanie, createdTime=Sun Oct 25 13:01:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40744, encodeId=6f4840e44de, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sat Oct 24 22:16:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373293, encodeId=036713e329341, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sat Oct 24 05:41:00 CST 2015, time=2015-10-24, status=1, ipAttribution=)]
    2016-04-03 luoxiaog

    #多中心#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2009639, encodeId=b2fa200963932, content=<a href='/topic/show?id=1b3f4410e62' target=_blank style='color:#2F92EE;'>#天士力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44107, encryptionId=1b3f4410e62, topicName=天士力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Nov 17 16:41:00 CST 2015, time=2015-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909484, encodeId=a4b2190948417, content=<a href='/topic/show?id=16c6430324c' target=_blank style='color:#2F92EE;'>#多中心研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43032, encryptionId=16c6430324c, topicName=多中心研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Tue Jul 12 05:41:00 CST 2016, time=2016-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703194, encodeId=869a1e031943c, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Fri Dec 25 14:41:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903901, encodeId=470e1903901c0, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sun Apr 03 05:41:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41372, encodeId=a253413e261, content=好药, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3911653185, createdName=1ddd0b24m59(暂无匿称), createdTime=Mon Oct 26 18:12:00 CST 2015, time=2015-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41129, encodeId=386a4112937, content=饭, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150904/IMG55E8DB68F05883098.jpg, createdBy=e00a1631985, createdName=fengzhigu, createdTime=Sun Oct 25 17:18:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41054, encodeId=7388410546f, content=中药需要国家投入去研究，肯定有大收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2be01625436, createdName=fatalmelanie, createdTime=Sun Oct 25 13:01:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41055, encodeId=dd3d41055c6, content=加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2be01625436, createdName=fatalmelanie, createdTime=Sun Oct 25 13:01:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40744, encodeId=6f4840e44de, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sat Oct 24 22:16:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373293, encodeId=036713e329341, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sat Oct 24 05:41:00 CST 2015, time=2015-10-24, status=1, ipAttribution=)]
    2015-10-26 1ddd0b24m59(暂无匿称)

    好药

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2009639, encodeId=b2fa200963932, content=<a href='/topic/show?id=1b3f4410e62' target=_blank style='color:#2F92EE;'>#天士力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44107, encryptionId=1b3f4410e62, topicName=天士力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Nov 17 16:41:00 CST 2015, time=2015-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909484, encodeId=a4b2190948417, content=<a href='/topic/show?id=16c6430324c' target=_blank style='color:#2F92EE;'>#多中心研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43032, encryptionId=16c6430324c, topicName=多中心研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Tue Jul 12 05:41:00 CST 2016, time=2016-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703194, encodeId=869a1e031943c, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Fri Dec 25 14:41:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903901, encodeId=470e1903901c0, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sun Apr 03 05:41:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41372, encodeId=a253413e261, content=好药, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3911653185, createdName=1ddd0b24m59(暂无匿称), createdTime=Mon Oct 26 18:12:00 CST 2015, time=2015-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41129, encodeId=386a4112937, content=饭, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150904/IMG55E8DB68F05883098.jpg, createdBy=e00a1631985, createdName=fengzhigu, createdTime=Sun Oct 25 17:18:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41054, encodeId=7388410546f, content=中药需要国家投入去研究，肯定有大收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2be01625436, createdName=fatalmelanie, createdTime=Sun Oct 25 13:01:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41055, encodeId=dd3d41055c6, content=加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2be01625436, createdName=fatalmelanie, createdTime=Sun Oct 25 13:01:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40744, encodeId=6f4840e44de, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sat Oct 24 22:16:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373293, encodeId=036713e329341, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sat Oct 24 05:41:00 CST 2015, time=2015-10-24, status=1, ipAttribution=)]
    2015-10-25 fengzhigu

    饭

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2009639, encodeId=b2fa200963932, content=<a href='/topic/show?id=1b3f4410e62' target=_blank style='color:#2F92EE;'>#天士力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44107, encryptionId=1b3f4410e62, topicName=天士力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Nov 17 16:41:00 CST 2015, time=2015-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909484, encodeId=a4b2190948417, content=<a href='/topic/show?id=16c6430324c' target=_blank style='color:#2F92EE;'>#多中心研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43032, encryptionId=16c6430324c, topicName=多中心研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Tue Jul 12 05:41:00 CST 2016, time=2016-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703194, encodeId=869a1e031943c, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Fri Dec 25 14:41:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903901, encodeId=470e1903901c0, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sun Apr 03 05:41:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41372, encodeId=a253413e261, content=好药, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3911653185, createdName=1ddd0b24m59(暂无匿称), createdTime=Mon Oct 26 18:12:00 CST 2015, time=2015-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41129, encodeId=386a4112937, content=饭, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150904/IMG55E8DB68F05883098.jpg, createdBy=e00a1631985, createdName=fengzhigu, createdTime=Sun Oct 25 17:18:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41054, encodeId=7388410546f, content=中药需要国家投入去研究，肯定有大收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2be01625436, createdName=fatalmelanie, createdTime=Sun Oct 25 13:01:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41055, encodeId=dd3d41055c6, content=加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2be01625436, createdName=fatalmelanie, createdTime=Sun Oct 25 13:01:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40744, encodeId=6f4840e44de, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sat Oct 24 22:16:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373293, encodeId=036713e329341, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sat Oct 24 05:41:00 CST 2015, time=2015-10-24, status=1, ipAttribution=)]
    2015-10-25 fatalmelanie

    中药需要国家投入去研究，肯定有大收获

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2009639, encodeId=b2fa200963932, content=<a href='/topic/show?id=1b3f4410e62' target=_blank style='color:#2F92EE;'>#天士力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44107, encryptionId=1b3f4410e62, topicName=天士力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Nov 17 16:41:00 CST 2015, time=2015-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909484, encodeId=a4b2190948417, content=<a href='/topic/show?id=16c6430324c' target=_blank style='color:#2F92EE;'>#多中心研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43032, encryptionId=16c6430324c, topicName=多中心研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Tue Jul 12 05:41:00 CST 2016, time=2016-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703194, encodeId=869a1e031943c, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Fri Dec 25 14:41:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903901, encodeId=470e1903901c0, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sun Apr 03 05:41:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41372, encodeId=a253413e261, content=好药, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3911653185, createdName=1ddd0b24m59(暂无匿称), createdTime=Mon Oct 26 18:12:00 CST 2015, time=2015-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41129, encodeId=386a4112937, content=饭, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150904/IMG55E8DB68F05883098.jpg, createdBy=e00a1631985, createdName=fengzhigu, createdTime=Sun Oct 25 17:18:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41054, encodeId=7388410546f, content=中药需要国家投入去研究，肯定有大收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2be01625436, createdName=fatalmelanie, createdTime=Sun Oct 25 13:01:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41055, encodeId=dd3d41055c6, content=加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2be01625436, createdName=fatalmelanie, createdTime=Sun Oct 25 13:01:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40744, encodeId=6f4840e44de, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sat Oct 24 22:16:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373293, encodeId=036713e329341, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sat Oct 24 05:41:00 CST 2015, time=2015-10-24, status=1, ipAttribution=)]
    2015-10-25 fatalmelanie

    加油

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2009639, encodeId=b2fa200963932, content=<a href='/topic/show?id=1b3f4410e62' target=_blank style='color:#2F92EE;'>#天士力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44107, encryptionId=1b3f4410e62, topicName=天士力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Nov 17 16:41:00 CST 2015, time=2015-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909484, encodeId=a4b2190948417, content=<a href='/topic/show?id=16c6430324c' target=_blank style='color:#2F92EE;'>#多中心研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43032, encryptionId=16c6430324c, topicName=多中心研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Tue Jul 12 05:41:00 CST 2016, time=2016-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703194, encodeId=869a1e031943c, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Fri Dec 25 14:41:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903901, encodeId=470e1903901c0, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sun Apr 03 05:41:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41372, encodeId=a253413e261, content=好药, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3911653185, createdName=1ddd0b24m59(暂无匿称), createdTime=Mon Oct 26 18:12:00 CST 2015, time=2015-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41129, encodeId=386a4112937, content=饭, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150904/IMG55E8DB68F05883098.jpg, createdBy=e00a1631985, createdName=fengzhigu, createdTime=Sun Oct 25 17:18:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41054, encodeId=7388410546f, content=中药需要国家投入去研究，肯定有大收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2be01625436, createdName=fatalmelanie, createdTime=Sun Oct 25 13:01:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41055, encodeId=dd3d41055c6, content=加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2be01625436, createdName=fatalmelanie, createdTime=Sun Oct 25 13:01:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40744, encodeId=6f4840e44de, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sat Oct 24 22:16:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373293, encodeId=036713e329341, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sat Oct 24 05:41:00 CST 2015, time=2015-10-24, status=1, ipAttribution=)]
    2015-10-24 sanshengshi

    赞

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2009639, encodeId=b2fa200963932, content=<a href='/topic/show?id=1b3f4410e62' target=_blank style='color:#2F92EE;'>#天士力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44107, encryptionId=1b3f4410e62, topicName=天士力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Nov 17 16:41:00 CST 2015, time=2015-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909484, encodeId=a4b2190948417, content=<a href='/topic/show?id=16c6430324c' target=_blank style='color:#2F92EE;'>#多中心研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43032, encryptionId=16c6430324c, topicName=多中心研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Tue Jul 12 05:41:00 CST 2016, time=2016-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703194, encodeId=869a1e031943c, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Fri Dec 25 14:41:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903901, encodeId=470e1903901c0, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sun Apr 03 05:41:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41372, encodeId=a253413e261, content=好药, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3911653185, createdName=1ddd0b24m59(暂无匿称), createdTime=Mon Oct 26 18:12:00 CST 2015, time=2015-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41129, encodeId=386a4112937, content=饭, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150904/IMG55E8DB68F05883098.jpg, createdBy=e00a1631985, createdName=fengzhigu, createdTime=Sun Oct 25 17:18:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41054, encodeId=7388410546f, content=中药需要国家投入去研究，肯定有大收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2be01625436, createdName=fatalmelanie, createdTime=Sun Oct 25 13:01:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41055, encodeId=dd3d41055c6, content=加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2be01625436, createdName=fatalmelanie, createdTime=Sun Oct 25 13:01:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40744, encodeId=6f4840e44de, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sat Oct 24 22:16:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373293, encodeId=036713e329341, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sat Oct 24 05:41:00 CST 2015, time=2015-10-24, status=1, ipAttribution=)]
    2015-10-24 yuanming7

    #心衰患者#

    0

以上为热门评论，梅斯医学App还有更多内容

相关资讯

Circ Heart Fail：心衰？多喝点甜菜根汁吧，有好处

心衰？多喝点甜菜根汁吧，有好处据发表于 Circulation: Heart Failure的一项研究表明，高硝酸盐（甜菜根汁中可大量发现）饮食可改善心衰患者的肌肉功能。硝酸盐是甜菜汁，菠菜及其他绿叶蔬菜(如芝麻菜和芹菜)的活性成分。研究人员曾发现，摄入高水平的硝酸盐可改善体育精英的肌肉性能。此次研究旨在探究甜菜汁是否有益于心衰患者的健康。研究仅纳入了9名患者，均接受甜菜汁治疗。采用双盲、自身对照

CSC&OCC 2015：胡盛寿：心力衰竭外科治疗——挑战与突破

本文作者：北京阜外心血管病医院院长，中国工程院院士，美国心脏病学院会员胡盛寿。心力衰竭是一种全球性疾病，欧洲有超过1000万，美国超过580万，中国超过500万人患有心力衰竭。30－65岁人群发病率为1.5-2.0%，65岁以上人群发病率为6-10%。心力衰竭是全球吃唯一呈增长趋势的心脏疾病，是心血管病领域未来要面临的巨大挑战。2003年，对中国10省市20个城区和农村15518人口调查显示，心衰

JACC：心衰患者可放心使用左心室辅助装置，既安全又有效

目前的研究中关于非正肌力药物依赖性心脏衰竭（HF）患者使用左心室辅助装置（LVAD）的数据是有限的。这项研究的目的是评估门诊HeartMate II（HMII）LVAD支持 vs 最佳的医疗管理（OMM）对于纽约心脏病协会功能分类为IIIB/ IV期的患者的效果，这些患者需符合LVAD目标治疗指征，但不依赖于静脉注射正性肌力药物的支持。这是一项前瞻性，多中心（N=41），200例（97例LVAD，

一周研究进展荟萃：让你知识满满！

通宵工作 癌细胞 β受体阻滞剂 睡眠 阿片类药物 心衰 动脉硬化

Circulation：增加体力活动可减少心衰的风险

以前的研究已经报道了体力活动（PA）和心脏衰竭（HF）的风险之间的负相关。然而，PA和HF风险之间的定量剂量-反应关系的全面评估还没有被报道。该前瞻性队列研究中，>18岁，并已报告了基线PA水平和HF事件有关联的参与者被纳入研究。研究人员使用随机效应模型对PA和HF风险之间的绝对剂量反应关系进行了评估。广义最小二乘回归模型被用来评估PA（MET-分钟/周）和各研究报告定量PA估计HF风险之间

JACC：心衰患者心脏康复治疗，你知道多少？

肯塔基，路易斯维尔大学医学院，Golwala H等人研究了心衰患者中心脏康复训练的使用率，趋势。其结果发表在8月份 Journal of the American College of Cardiology期刊上。背景：目前指南推荐病情稳定的门诊心脏衰竭（HF）患者进行心脏康复训练（CR）;然而，现实世界中，心衰患者与心脏康复治疗相关的治疗趋势及其影响因素并不完全已知。目的：这项研究旨在评估失代偿